Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma has announced the filing of a prospectus supplement with the SEC for a new At-The-Market (“ATM”) program, allowing for the offering of up to $75 million of American Depositary Shares (“ADS”). This program follows the termination of a previous ATM program as of April 19, 2023. The funds from this new initiative are intended for research, development, and working capital. The maximum potential dilution from these offerings could reach approximately 22.97%, based on current share capital. Future offerings will be conducted through an approved sales agreement with Jefferies. Additionally, the 2023 Annual General Meeting on May 12, 2023 may introduce new resolutions for further capital increases, which could impact existing shareholders' stakes.

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) announced its participation in the Van Lanschot Kempen Life Sciences Conference 2023 on April 25-26 in Amsterdam. The company specializes in developing immunotherapies for cancer, leveraging its proprietary ANKET® platform. Key programs include lacutamab, targeting cutaneous and peripheral T cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca to enhance innovation. Headquartered in Marseille, France, Innate Pharma is committed to advancing cancer treatment through its clinical-stage biotechnology.

Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reported its total number of shares outstanding and voting rights as of April 1, 2023. The company has a total of 80,222,007 ordinary shares and 6,514 and 7,581 preferred shares from 2016 and 2017, respectively. The total number of theoretical voting rights stands at 80,979,847, with 80,961,272 exercisable voting rights. These figures comply with the French 'Code de Commerce' and AMF regulations. As a clinical-stage biotechnology firm, Innate focuses on developing immunotherapies for cancer using its proprietary ANKET® platform, partnering with major firms like Sanofi and AstraZeneca to enhance its R&D efforts.

Innate Pharma will hold its Annual General Meeting (AGM) on May 12, 2023, at 10:30 a.m. CEST in Marseille, France. The meeting will be broadcast live, providing shareholders access to discuss the agenda and proposed resolutions.

Shareholders must register their shares at least two business days before the AGM. Those holding bearer shares need to secure a 'certificate of shareholding' from their brokers. Written questions must be submitted by email at least two business days prior to the meeting.

The company is actively developing immunotherapies for cancer patients through its innovative ANKET® platform and collaborations with partners like Sanofi and AstraZeneca.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has filed its 2022 Universal Registration Document with the AMF and its annual report on Form 20-F with the SEC for the year ending December 31, 2022. These filings provide comprehensive insights into the company's operations and financial performance. The Universal Registration Document can be accessed via AMF's website, and the Form 20-F is available on the SEC's website. Innate Pharma is developing innovative immunotherapies, leveraging its proprietary ANKET platform. Its lead program, lacutamab, targets advanced forms of cutaneous and peripheral T cell lymphomas, while collaborating with partners like AstraZeneca.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced an exclusive license agreement with Takeda for developing antibody drug conjugates (ADC) targeting an undisclosed area, focusing on Celiac disease. Takeda will manage the development, manufacturing, and commercialization of products. Innate will receive a $5 million upfront payment and could earn up to $410 million in future milestone payments, plus royalties on net sales. This collaboration aims to leverage Innate's antibody engineering expertise, expanding its scientific applications beyond oncology.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) expanded its collaboration with Sanofi on NK cell engager therapeutics, receiving a €25 million upfront payment. The company also reported encouraging preliminary efficacy data for lacutamab in advanced cutaneous T cell lymphoma, with a global objective response rate (ORR) of 28.6%. Additionally, the first patient was dosed in the Phase 3 PACIFIC-9 trial for lung cancer, triggering a $50 million milestone payment from AstraZeneca. As of December 31, 2022, Innate's cash position was €136.6 million, supporting operations into mid-2025. The company aims for key clinical milestones in 2023.

On March 1, 2023, Innate Pharma SA announced its total number of shares outstanding and voting rights as required by French regulations. The company has 80,218,457 ordinary shares and 6,514 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights stands at 80,976,297, with exercisable voting rights at 80,957,722. Innate Pharma focuses on oncology, striving to improve patient outcomes through therapeutic antibodies. The company has established significant partnerships with major biopharmaceutical firms.

Innate Pharma announced a conference call set for March 23, 2023, at 2 p.m. CET for discussing its financial results for the full year ending December 31, 2022. The call will feature key executives, including CEO Mondher Mahjoubi and CFO Frédéric Lombard. Interested parties can join via a webcast or telephone registration. Innate Pharma is focused on developing therapeutic antibodies aimed at enhancing cancer treatment, boasting a diverse pipeline and collaborations with major biopharmaceutical companies like Bristol-Myers Squibb and AstraZeneca. For more information, visit www.innate-pharma.com.